Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
STAT+
Health
Coronavirus
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophy

  • Adam Feuerstein

By Adam Feuerstein July 29, 2022

Reprints
Sarepta - Cambridge -AP
Kristoffer Tripplaar/Sipa via AP

Sarepta Therapeutics said Friday that it intends seek regulators’ approval for its gene therapy to treat Duchenne muscular dystrophy earlier than expected — a risky move but one that could help the company reach the market much faster.

In early Friday trading, Sarepta shares rose 12% to $96.50.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Create a display name to comment

This name will appear with your comment

Will low-dose vaccination stretch the monkeypox vaccine supply, or…
Will low-dose vaccination stretch the monkeypox vaccine supply, or backfire?
As billionaires race to fund anti-aging projects, a much-discussed…
As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked
In a massive victory for Democrats, Medicare is poised…
In a massive victory for Democrats, Medicare is poised to negotiate drug prices
Amid Aduhelm woes, Biogen moves to pare back office…
Amid Aduhelm woes, Biogen moves to pare back office space
Pharmalittle: Endo bankruptcy filing over opioid crisis appears imminent;…
Pharmalittle: Endo bankruptcy filing over opioid crisis appears imminent; U.S. to allow fractional doses of monkeypox…
Everything you need to know before the next big…
Everything you need to know before the next big Alzheimer’s readout

Recommended Stories